# The roles and heterogeneity of CD8+ T cells in inflammatory bowel disease: A narrative review of insights from single-cell transcriptomics (Review)

**Authors:** Rui Zhong, Jing Guo, Wujie Ye, Zhihui Deng, Huangan Wu, Qin Qi, Guona Li, Lu Zhu, Yan Huang, Luyi Wu

PMC · DOI: 10.3892/ijmm.2026.5801 · International Journal of Molecular Medicine · 2026-03-17

## TL;DR

This review explores how different types of CD8+ T cells contribute to inflammatory bowel disease using detailed genetic analysis.

## Contribution

The paper highlights new insights into the diverse roles of CD8+ T cells in IBD through single-cell transcriptomics.

## Key findings

- CD8+ T cells in IBD show significant phenotypic and functional diversity.
- Distinct CD8+ T cell subsets have unique signaling pathway activation profiles linked to clinical outcomes.
- These cells interact with other cell types to influence inflammation and tissue balance in IBD.

## Abstract

The present review investigates the role and characteristics of CD8+ T cells in inflammatory bowel disease (IBD) using single-cell transcriptomics, revealing their pivotal functions and remarkable heterogeneity. In IBD, CD8+ T cells exhibit marked phenotypic and functional diversity, with distinct subpopulations exhibiting unique signaling pathway activation profiles that associate with varying clinical outcomes. Furthermore, CD8+ T cell subsets in IBD participate in complex crosstalk networks involving immune and non-immune cells, modulating inflammatory responses and tissue homeostasis. The present review synthesizes the dynamic complexity of CD8+ T cell behavior in IBD and identifies promising therapeutic opportunities through targeted modulation of specific T cell subsets and their interactions within the colonic microenvironment.

## Linked entities

- **Diseases:** inflammatory bowel disease (MONDO:0005265), IBD (MONDO:0005265)

## Full-text entities

- **Genes:** BACH2 (BACH transcriptional regulator 2) [NCBI Gene 60468] {aka BTBD25, IMD60}, TNFRSF18 (TNF receptor superfamily member 18) [NCBI Gene 8784] {aka AITR, CD357, ENERGEN, GITR, GITR-D}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, TNFRSF4 (TNF receptor superfamily member 4) [NCBI Gene 7293] {aka ACT35, CD134, IMD16, OX40, TXGP1L}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, IL2RB (interleukin 2 receptor subunit beta) [NCBI Gene 3560] {aka CD122, IL15RB, IMD63, P70-75}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL23R (interleukin 23 receptor) [NCBI Gene 149233] {aka PSORS7}, CRTAM (cytotoxic and regulatory T cell molecule) [NCBI Gene 56253] {aka CD355}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IGKV1D-27 (immunoglobulin kappa variable 1D-27 (pseudogene)) [NCBI Gene 28898] {aka A4, A4a, IGKV1D27}, GZMK (granzyme K) [NCBI Gene 3003] {aka GrK, TRYP2}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, GZMA (granzyme A) [NCBI Gene 3001] {aka CTLA3, HFSP}, GZMH (granzyme H) [NCBI Gene 2999] {aka CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, KLRG1 (killer cell lectin like receptor G1) [NCBI Gene 10219] {aka 2F1, CLEC15A, MAFA, MAFA-2F1, MAFA-L, MAFA-LIKE}, EOMES (eomesodermin) [NCBI Gene 8320] {aka TBR2}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, NCR3 (natural cytotoxicity triggering receptor 3) [NCBI Gene 259197] {aka 1C7, CD337, LY117, MALS, NKp30}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, CD1D (CD1d molecule) [NCBI Gene 912] {aka R3, R3G1}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, FGFBP2 (fibroblast growth factor binding protein 2) [NCBI Gene 83888] {aka HBP17RP, KSP37}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380] {aka B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2}, KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, TYROBP (transmembrane immune signaling adaptor TYROBP) [NCBI Gene 7305] {aka DAP12, KARAP, PLOSL, PLOSL1}, KLRD1 (killer cell lectin like receptor D1) [NCBI Gene 3824] {aka CD94}, KLRB1 (killer cell lectin like receptor B1) [NCBI Gene 3820] {aka CD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A}, ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) [NCBI Gene 953] {aka ATP-DPH, ATPDase, CD39, NTPDase-1, SPG64}, NOD2 (nucleotide binding oligomerization domain containing 2) [NCBI Gene 64127] {aka ACUG, BLAU, BLAUS, CARD15, CD, CLR16.3}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176] {aka ECTD1, ECTD17, LEF-1, TCF10, TCF1ALPHA, TCF7L3}, CEACAM5 (CEA cell adhesion molecule 5) [NCBI Gene 1048] {aka CD66e, CEA}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}
- **Diseases:** TRM (MESH:D001260), breast cancer (MESH:D001943), cytotoxic (MESH:D064420), acute pancreatitis (MESH:D010195), non-small cell lung cancer (MESH:D002289), immune dysregulation (OMIM:614878), fatigue (MESH:D005221), colitis (MESH:D003092), bladder cancer (MESH:D001749), liver cancer (MESH:D006528), immune-mediated disorders (MESH:C567355), deep vein thrombosis (MESH:D020246), immunodeficient (MESH:D007153), head and neck cancer (MESH:D006258), visceral pain (MESH:D059265), colorectal cancer (MESH:D015179), COVID-19 (MESH:D000086382), hypersensitivity (MESH:D004342), inflammation (MESH:D007249), CPI (MESH:D054179), IBD (MESH:D015212), somnolence (MESH:D006970), metabolic dysregulation (MESH:D021081), epithelial damage (MESH:D009375), melanoma (MESH:D008545), peripheral neuropathy (MESH:D010523), disorders of the gastrointestinal tract (MESH:D005770), intestinal immune disorder (MESH:D007410), tissue damage (MESH:D017695), UC (MESH:D003093), CD (MESH:D003424), malignancies (MESH:D009369)
- **Chemicals:** Ontamalimab (MESH:C000597368), DSS (MESH:D016264), steroid (MESH:D013256), mirikizumab (MESH:C000708407), AZA (MESH:D001379), CsA (MESH:D016572), GLM (MESH:C529000), glucose (MESH:D005947), lipid (MESH:D008055), Natalizumab (MESH:D000069442), Etrolizumab (MESH:C559198), ADA (MESH:D000068879), tacrolimus (MESH:D016559), vedolizumab (MESH:C543529), 6-thioguanine (MESH:D013866), IFX (MESH:D000069285), Thalidomide (MESH:D013792), 2,4,6-trinitrobenzene sulfonic acid (-), 5-ASA (MESH:D019804), CZP (MESH:D000068582), MTX (MESH:D008727), UST (MESH:D000069549), RIS (MESH:C000601773)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13034893/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13034893/full.md

## References

157 references — full list in the complete paper: https://tomesphere.com/paper/PMC13034893/full.md

---
Source: https://tomesphere.com/paper/PMC13034893